<--- Back to Details
First PageDocument Content
Serine protease inhibitors / Coagulation system / Antifibrinolytics / Fibrinolysis / Plasmin / Alpha 2-antiplasmin / Coagulation / Disseminated intravascular coagulation / Serpin / Blood / Anatomy / Acute phase proteins
Date: 2014-04-22 11:47:02
Serine protease inhibitors
Coagulation system
Antifibrinolytics
Fibrinolysis
Plasmin
Alpha 2-antiplasmin
Coagulation
Disseminated intravascular coagulation
Serpin
Blood
Anatomy
Acute phase proteins

α2-Antiplasmin and its deficiency: fibrinolysis out of balance

Add to Reading List

Source URL: www.hemophilia.org

Download Document from Source Website

File Size: 96,77 KB

Share Document on Facebook

Similar Documents

Blood / Medicine / Anatomy / Transfusion medicine / Hematology / Blood products / Coagulation system / Platelet / Blood transfusion / Hematocrit / Bleeding / Blood type

Center Information: Subcenter: Inland Northwest Blood Center Inland Northwest Blood Center 210 W. Cataldo Ave.

DocID: 1riKA - View Document

Cell biology / Biology / Blood / Programmed cell death / Apoptosis / Coagulation system / Cell signaling / Induced stem cells / Caspase / Platelet / Thrombopoiesis / Angiogenesis

Microsoft Wordfile00

DocID: 1r9dZ - View Document

Blood / Coagulation system / Anatomy / CSL Behring / Von Willebrand disease / Factor VIII / Coagulation / CSL Limited / Hereditary angioedema / Haemophilia / Factor IX / Factor VII

News Releases Global Home | CSL Behring US | CSL Plasma | All CSL Behring Web Sites  

DocID: 1qHpD - View Document

Medicine / Coagulation system / Thrombin / Antibody / Syringe / Surgical suture / Draft:Professor Dr. S Tsakas II

RECOTHROM, Thrombin topical (Recombinant) Package Insert

DocID: 1qv5K - View Document

Finance / Money / Economy / Transfusion medicine / Blood products / Corporate finance / Venture capital / Coagulation system / Platelet / Nesta / Bleeding / Seed money

Quester leads £3.1million investment in Haemostatix 23 January 2006 – Quester, a leading UK venture capital company, announced today that it has led a £3.1million investment in Haemostatix Ltd, a drug design and deve

DocID: 1qk7W - View Document